Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 2, 2013, Pages

  Farnham, Paul G ^a   Holtgrave, David R ^b   Gopalappa, Chaitra ^c   Hutchinson, Angela B ^a   Sansom, Stephanie L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c AVENIR HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LETTER; LIFE EXPECTANCY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; VIRUS LOAD;

ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84885219906     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a5c8d4     Document Type: Letter

References (27)

1. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352: 570-585.
2. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005;352: 586-595.
3. Prabhu VS, Farnham PG, Hutchinson AB, et al. Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis. PLoS One. 2011;6:e19936.
4. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Inter Med. 2010;153: 778-789.
5. Sorensen SW, Sansom SL, Brooks JT, et al. A mathematical model of comprehensive testand- treat services and HIV incidence among men who have sex with men in the United States. PLoS One. 2012;7:e29098.
6. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr. 1997;16: 54-62.
7. Pinkerton SD, Holtgrave DR. A method for evaluating the economic efficiency of HIV behavioral risk reduction interventions. AIDS Behav. 1998;2: 189-201.
8. Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in U.S. clinical settings. Med Decis Making. 2012;32: 459-469.
9. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003; 163: 1637-1641.
10. Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted lifeyear decision rule? [article]. Med Care. 2008;46: 349-356.
11. Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? [editorial]. Med Care. 2008;46: 343-345.
12. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44: 990-997.
13. Hutchinson AB, Patel P, Sansom SL, et al. Costeffectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med. 2010;7:e1000342.
14. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22: 475-481.
15. Holtgrave D, Wolitski R, Pals S, et al. Costutility analysis of the housing and health intervention for homeless and unstably housed persons living with HIV. AIDS Behav. 2013; 17: 1626-1631.
16. Farnham PG, Gopalappa C, Sansom SL, et al. Updates of lifetime costs of care and quality of life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64: 183-189.
17. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 U.S. dependent areas-2010. HIV Surveill Suppl Rep. 2013;18 (no. 2, part B): 1-25.
18. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365: 493-505.
19. Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012;7: 99-105. 110.1097/COH. 1090b1013e32834f32835cf32832.
20. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52: 793-800.
21. Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment-United States. MMWR Morb Mortal Wkly Rep. 2011;60: 1618-1623.
22. Centers for Disease Control and Prevention. CDC fact sheet: HIV in the United States: the stages of care. 2012. Available at: www.cdc. gov/nchhstp/newsroom/docs/2012/Stages-ofcareFactSheet- 508.pdf. Accessed September 10, 2012.
23. Buchacz K, RangelM, Blacher R, et al. Changes in the clinical epidemiology of HIV infection in the United States: Implications for the clinician. Curr Infect Dis Rep. 2009;11: 75-83.
24. Buchacz K, Baker RK, Palella FJ, et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral- treated HIV-infected adults in the US. Antivir Ther. 2013;18: 65-75.
25. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50: 1387-1396.
26. Isogai PK, Rueda S, Rachlis AR, et al. Prediction of health preference values from CD4 counts in individuals with HIV. Med Decis Making. 2013;33: 558-566.
27. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. Washington, DC: The White House; 2010.